HOME >> MEDICINE >> NEWS
Genetically modified cells migrate to brain and treat neurodegeneration in St. Jude model

Physicians might one day be able to treat a disease that destroys brain cells in children using genetically modified cells to transport a "drug" to the site of the dying neural cells (cells that transmit impulses). This discovery occurred based on results of a laboratory study of the technique published by investigators at St. Jude Children's Research Hospital. A report on this work appears in the prepublication online issue of Blood.

There is currently no cure for such disorders, which are called lysosomal storage diseases (LSDs).

The St. Jude researchers successfully treated a laboratory model of an LSD called GM1 gangliosidosis using bone marrow cells (BMCs) into which scientists inserted the gene for an enzyme that breaks down a fat molecule called GM1. GM1 is a critical component of normal brain cells. But in GM1 gangliosidosis, brain cells lack this enzyme--beta-galactosidase--and GM1 accumulates to such a high concentration that it disrupts the proper function of the cell and causes it to self-destruct. BMCs include a population of so-called pluripotent stem cells--cells that give rise to a variety of different cell types that have specific functions, such as the immune cells called monocytes.

After the St. Jude team infused the genetically modified BMCs into the laboratory model, resulting monocytes migrated to the degenerating brain cells that lacked the gene for beta-galactosidase. These cells took in the enzyme released by the monocytes and used it to break down excess GM1, thus correcting the potentially fatal buildup of this molecule.

The monocytes homed in on the brain by following a trail of signaling molecules that were released by cells adjacent to the degenerating neurons, according to Alessandra d'Azzo, Ph.D., a member of the St. Jude department of Genetics and Tumor Cell Biology. Such signaling proteins are called chemokines. Under a disease condition, these brain cells, called astrocytes and microglia, release chemokines
'"/>

Contact: Kelly Perry
kelly.perry@stjude.org
901-495-3306
St. Jude Children's Research Hospital
22-Jun-2005


Page: 1 2 3

Related medicine news :

1. Genetically modified cells attack tumors
2. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
3. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
4. New algorithm matches any tumor cells to best possible anti-cancer treatments
5. Aging stem cells in mice may hold answers to diseases of the aged, Stanford study finds
6. Loss of stem cells correlates with premature aging in animal study
7. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
8. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
9. Stanford researchers track human stem cells transplanted into rat brain
10. Nurse cells make life and death decisions for infection-fighting cells
11. Adult brain cells rediscover their inner child

Post Your Comments:
(Date:11/27/2014)... 2014 HealthPostures, a leading ... , has announced that it has entered into ... The partnership will put HealthPostures' products into central ... In addition to having its products sold through ... HealthPostures' products with the business decision makers in ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
(Date:11/27/2014)... November 27, 2014 Allowing children to help ... during school, helps give children responsibility, ownership, boosts self-esteem, and ... , Now, the real question is, how do you ... secret? According to a study published by Child Development Journal, ... a dramatic effect on a child’s willingness to lend a ...
(Date:11/27/2014)... 27, 2014 At The Little Gym, ... it came as no surprise when a recent study ... academic success. The Journal of Pediatrics found ... motor tasks during the school years may be important ... development.” The study monitored two groups of children; those ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
Breaking Medicine News(10 mins):Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
(Date:11/26/2014)... 26, 2014  Cohen, Placitella & Roth, PC ... who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") ... from January 31, 2011 through November 2, 2014 ... certain of its officers and directors publically disseminated ... Sections 10(b) and 20(a) of the Securities Exchange ...
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... U.S. Food and Drug Administration (FDA) has issued ... Application (NDA) for AVP-825. AVP-825 is an investigational ... delivered intranasally utilizing a novel Breath Powered delivery ... letter, and consistent with the preliminary feedback announced ...
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the Bank ... , , , Date: , , , Wednesday, December ... 2:50 p.m. EST , , , , Location: , , ... About BioScrip, Inc. BioScrip, Inc. ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
Cached News: